Drug class
Programmed cell death protein 1 (PD-1)-blocking monoclonal antibody; immune checkpoint inhibitor
Mechanism of action
Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, relieving PD-1-mediated inhibitory signalling and restoring antitumour T-cell activity.
General use cases
- In combination with gemcitabine and cisplatin or carboplatin for first-line treatment of adults with recurrent or metastatic non-keratinising nasopharyngeal carcinoma.
- As monotherapy for adults with metastatic non-keratinising nasopharyngeal carcinoma that has progressed on or after platinum-based chemotherapy and at least one other prior line of therapy, under the US indication.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
